A roundup of biopharma news and updates includes Merck and Eisai’s Keytruda-Lenvima combo hitting the mark in a Phase III study for advanced endometrial cancer.
UCB S.A. is flexing the company’s M&A muscles once again with the acquisition of Handl Therapeutics BV, a rapidly growing and transformative gene therapy company based in Leuven, Belgium.
Bayer is making a big bet on gene therapy with the acquisition of North Carolina-based Asklepios BioPharmaceutical (AskBio).
Dyno Therapeutics announced a licensing and collaboration deal with Roche worth up to $1.8 billion to apply the Cambridge, Mass.-based company’s CapsidMap platform to the development of adeno-associated virus (AAV) vectors for gene therapies for central nervous system diseases and liver-directed therapies.
Shares of Voyager Therapeutics were down in trading after the company announced a clinical hold was placed on an experimental gene therapy treatment for Huntington’s disease before heading into the clinic.
Shares of Solid Biosciences skyrocketed in trading after the company announced the U.S. Food and Drug Administration lifted the clinical hold on the IGNITE DMD Phase I/II clinical trial.
The U.S. Food and Drug Administration’s approval-review schedule for August includes the Biologics License Application for Bristol Myers Squibb and Juno Therapeutics’ lisocabtagene maraleucel (liso-cel) for relapsed or refractory large B-cell lymphoma after at least two previous therapies.
Passage Bio’s first attempt to develop a GM1 gangliosidosis gene therapy treatment ran into a roadblock in the form of a clinical hold.
Gene therapy pioneer uniQure launched the first-in-human adeno-associated virus-based gene therapy clinical trial for Huntington’s disease.
Locanabio combines gene therapy with RNA modification for a novel, highly flexible platform that can modify, replace or eliminate dysfunctional RNA.